EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Clinical Potential of GIP in Type 2 Diabetes and Obesity

Michael Nauck iD, Fiona Gribble iD, Frank Reimann, David A D'Alessio, Jonathan E Campbell iD

Diabetes Care · 2026

DOI: 10.2337/dci25-0141 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes Care, 2026. Verfasst von Michael Nauck und 4 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes, Endocrinology, Metabolism Section, Medical Department I, Katholisches Klinikum Bochum, Sankt Josef-Hospital, Ruhr-University, Bochum, Germa…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Gastric Inhibitory Polypeptide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Wellcome Trust, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Incretin-based pharmacology has revolutionized the medical treatment of type 2 diabetes and obesity. The most effective drug to date is tirzepatide, a dual incretin receptor agonist that engages both the glucagon-like peptide 1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). While the relative contributions of GIPR and GLP-1R actions to the clinical effects of tirzepatide have not been established, the potency of this agent has reignited interest in the clinical potential of GIPR agonism. Here, we discuss incretin biology as it relates to metabolic pharmacology and contextualize the mechanisms by which GIPR activity could contribute to the development of new and effective drugs. We explore current and future applications of GIPR agonists and antagonists, to underscore the potential that this signaling system could add to treatment of type 2 diabetes and obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2ObesityGastric Inhibitory PolypeptideHumansReceptors, Gastrointestinal HormoneIncretinsTirzepatideAnimalsGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor Agonists

Substanzen

Gastric Inhibitory Polypeptidegastric inhibitory polypeptide receptorReceptors, Gastrointestinal HormoneIncretinsTirzepatideGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Diabetes, Endocrinology, Metabolism Section, Medical Department I, Katholisches Klinikum Bochum, Sankt Josef-Hospital, Ruhr-University, Bochum, Germany.
  • Institute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.
  • Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Addenbrooke's Hospital, Cambridge, U.K.
  • Duke Molecular Physiology Institute, Durham, NC.
  • Division of Endocrinology, Department of Medicine, Duke University, Durham, NC.
  • Department of Pharmacology and Cancer Biology, Duke University, Durham, NC.

ORCID-Profile: Michael Nauck, Fiona Gribble, Jonathan E Campbell

Förderung

  • NIDDK NIH HHS
  • Wellcome Trust
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Nauck, M., Gribble, F., Reimann, F., D'Alessio, D. A., & Campbell, J. E. (2026). Clinical Potential of GIP in Type 2 Diabetes and Obesity. Diabetes Care. https://doi.org/10.2337/dci25-0141

Vancouver

Nauck M, Gribble F, Reimann F, D'Alessio DA, Campbell JE. Clinical Potential of GIP in Type 2 Diabetes and Obesity. Diabetes Care. 2026. doi:10.2337/dci25-0141

BibTeX
@article{Nauck2026,
  author = {Nauck, Michael and Gribble, Fiona and Reimann, Frank and D'Alessio, David A and Campbell, Jonathan E},
  title = {Clinical Potential of GIP in Type 2 Diabetes and Obesity},
  journal = {Diabetes Care},
  year = {2026},
  doi = {10.2337/dci25-0141}
}
Kostenlos starten →